Hormonal
GDF-15 exhibits a dual role in cardiovascular health: it is cardioprotective against ischemia and hypertrophy via Smad and PI3K/AKT pathways, but its chronic elevation is associated with the progression of atherosclerosis and plaque instability.
Understanding GDF-15 helps explain why heart stress markers rise in disease. Managing cardiovascular risk factors (blood pressure, cholesterol, glucose) reduces the tissue stress that triggers GDF-15, potentially mitigating its negative long-term associations while allowing its protective acute effects to function.
GDF-15 protects heart, adipose tissue, and endothelial cells by inhibiting JNK (c-Jun N-terminal kinase), Bad (Bcl-2-associated death promoter), and EGFR (epidermal growth factor receptor) and activating Smad, eNOS, PI3K, and AKT signaling pathways.
Why this rating
Supported by multiple animal studies and human observational data detailing specific molecular pathways.
Source
GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective
Ramu Adela et al. · Journal of Diabetes Research · 2015
DOI 10.1155/2015/490842
More from this paper
- Elevated circulating levels of Growth Differentiation Factor-15 (GDF-15) serve as a robust prognostic biomarker for cardiovascular mortality, heart failure severity, and all-cause mortality in patients with diabetes and cardiovascular diseases.Good
- GDF-15 acts as a metabolic regulator that decreases food intake, body weight, and adiposity, and improves glucose tolerance, suggesting a potential therapeutic target for obesity and insulin resistance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →